Last reviewed · How we verify
Standard Clinical Practice Regimen
This drug works by inhibiting the reuptake of serotonin and norepinephrine in the brain.
This drug works by inhibiting the reuptake of serotonin and norepinephrine in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | Standard Clinical Practice Regimen |
|---|---|
| Also known as | 18 months Forteo followed by 18 months Prolia |
| Sponsor | Health Research, Inc. |
| Drug class | SSRI |
| Target | SERT, NET |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By increasing the levels of these neurotransmitters, it helps to improve mood and reduce symptoms of depression and anxiety. This is achieved through the inhibition of the serotonin and norepinephrine reuptake transporters (SERT and NET), leading to an increase in the concentration of these neurotransmitters in the synaptic cleft.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Fatigue
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis (PHASE2, PHASE3)
- A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure
- Effectiveness of Stanley Paris Manual Therapy vs. Conventional Physiotherapy in Reducing Pain and Improving Function in Grade II Knee Osteoarthritis (NA)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity (PHASE2, PHASE3)
- PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Clinical Practice Regimen CI brief — competitive landscape report
- Standard Clinical Practice Regimen updates RSS · CI watch RSS
- Health Research, Inc. portfolio CI